Medium Term Outcomes of Bypass Surgery for Recurrent Superficial Femoral Artery Lesions After Endovascular Treatment.

IF 0.7
Hitoshi Tachibana, Taira Kobayashi, Takanobu Okazaki, Shingo Mochizuki, Kazuki Maeda, Hiroshi Kodama, Mayo Oshita, Miwa Arakawa, Akira Katayama, Shinya Takahashi
{"title":"Medium Term Outcomes of Bypass Surgery for Recurrent Superficial Femoral Artery Lesions After Endovascular Treatment.","authors":"Hitoshi Tachibana, Taira Kobayashi, Takanobu Okazaki, Shingo Mochizuki, Kazuki Maeda, Hiroshi Kodama, Mayo Oshita, Miwa Arakawa, Akira Katayama, Shinya Takahashi","doi":"10.1177/15385744251387657","DOIUrl":null,"url":null,"abstract":"<p><p>ObjectiveThe study was performed to examine clinical outcomes of bypass surgery for recurrent superficial femoral artery (SFA) occlusive lesions after endovascular treatment (EVT).MethodPatients who underwent bypass surgery for a recurrent SFA lesion after EVT at 4 Japanese vascular centers from 2015 to 2020 were analyzed retrospectively. The primary endpoint was graft patency (primary, assisted primary, and secondary).ResultsA total of 46 patients were included in the study. The patients had high rates of hypertension (85%), diabetes (70%), and chronic kidney disease (63%). Clinical presentation before EVT was intermittent claudication in 16 cases (35%) and chronic limb-threatening ischemia in 30 cases (65%). Initial EVT was performed for complex SFA lesions (lesion length, 200 [125-260] mm; reference vessel diameter, 5.3 [4.7-6.0] mm; chronic total occlusion, 50%; poor below-the-knee runoff vessel, 60%). The final device was a bare-nitinol stent in 26 cases (56%), stent graft in 9 (20%), and drug-eluting stent in 7 (15%). A total of 46 surgical reconstructions (above-the-knee femoropopliteal bypass, 15 (33%); below-the-knee femoropopliteal bypass, 7 (15%); tibial bypass, 24 (52%)) were performed using autologous vein grafts (72%) and prosthesis grafts (28%) in a median period of 300 [145-556] days from initial EVT. The median procedure time was 201 [159-299] min. No case had early graft occlusion or hospital death within 30 days. The median follow-up period was 27 (12.7-49.2) months. The 3-year primary, assisted primary, and secondary graft patencies were 57%, 70%, and 77%, respectively; the 3-year limb salvage was 84%; and the 3-year survival was 66%.ConclusionMedium term outcomes were acceptable in patients with bypass surgery for a recurrent SFA lesion after EVT.</p>","PeriodicalId":94265,"journal":{"name":"Vascular and endovascular surgery","volume":" ","pages":"15385744251387657"},"PeriodicalIF":0.7000,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vascular and endovascular surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/15385744251387657","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

ObjectiveThe study was performed to examine clinical outcomes of bypass surgery for recurrent superficial femoral artery (SFA) occlusive lesions after endovascular treatment (EVT).MethodPatients who underwent bypass surgery for a recurrent SFA lesion after EVT at 4 Japanese vascular centers from 2015 to 2020 were analyzed retrospectively. The primary endpoint was graft patency (primary, assisted primary, and secondary).ResultsA total of 46 patients were included in the study. The patients had high rates of hypertension (85%), diabetes (70%), and chronic kidney disease (63%). Clinical presentation before EVT was intermittent claudication in 16 cases (35%) and chronic limb-threatening ischemia in 30 cases (65%). Initial EVT was performed for complex SFA lesions (lesion length, 200 [125-260] mm; reference vessel diameter, 5.3 [4.7-6.0] mm; chronic total occlusion, 50%; poor below-the-knee runoff vessel, 60%). The final device was a bare-nitinol stent in 26 cases (56%), stent graft in 9 (20%), and drug-eluting stent in 7 (15%). A total of 46 surgical reconstructions (above-the-knee femoropopliteal bypass, 15 (33%); below-the-knee femoropopliteal bypass, 7 (15%); tibial bypass, 24 (52%)) were performed using autologous vein grafts (72%) and prosthesis grafts (28%) in a median period of 300 [145-556] days from initial EVT. The median procedure time was 201 [159-299] min. No case had early graft occlusion or hospital death within 30 days. The median follow-up period was 27 (12.7-49.2) months. The 3-year primary, assisted primary, and secondary graft patencies were 57%, 70%, and 77%, respectively; the 3-year limb salvage was 84%; and the 3-year survival was 66%.ConclusionMedium term outcomes were acceptable in patients with bypass surgery for a recurrent SFA lesion after EVT.

血管内治疗后复发性股浅动脉病变的搭桥手术中期疗效。
目的探讨血管内治疗(EVT)后复发性股浅动脉(SFA)闭塞病变的搭桥手术的临床效果。方法回顾性分析2015 - 2020年日本4个血管中心EVT术后复发性SFA病变行搭桥手术的患者。主要终点是移植物通畅(原发性、辅助原发性和继发性)。结果共纳入46例患者。这些患者有高血压(85%)、糖尿病(70%)和慢性肾病(63%)的高发率。EVT前的临床表现为间歇性跛行16例(35%),慢性肢体缺血30例(65%)。初始EVT用于复杂SFA病变(病变长度200 [125-260]mm;参考血管直径5.3 [4.7-6.0]mm;慢性全闭塞50%;膝关节以下径流血管不良60%)。最终装置为裸镍钛诺支架26例(56%),支架移植9例(20%),药物洗脱支架7例(15%)。手术重建共46例(膝上股腘搭桥15例(33%);膝以下股腘动脉旁路,7例(15%);在首次EVT后300[145-556]天的中位时间内,使用自体静脉移植物(72%)和假体移植物(28%)进行了24例(52%)的胫骨旁路手术。手术时间中位数为201[159-299]分钟。30天内无一例发生早期移植物闭塞或院内死亡。中位随访时间为27(12.7-49.2)个月。3年原发、辅助原发和继发移植通畅率分别为57%、70%和77%;3年肢体保留率为84%;3年生存率为66%。结论EVT后SFA复发患者行搭桥手术中期预后可接受。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信